Market accessOfficial

Health Canada posts Olympus recall over loaned surgical devices used on animals, then reissued to hospitals

🇨🇦 Health Canada · Wed 04 Nov 2026

Olympus devices loaned to customers were wrongly used for animal purposes, reprocessed and then sent to hospitals for human use, prompting a Type II recall with sterility concerns.

Health Canada has published a Type II recall covering a wide range of Olympus Medical Systems Corp. surgical devices, after the company found that some loaned units had been wrongly allocated and used for animal purposes. The notice, dated 4 November 2026, gives a recall date of 14 October 2026 and the identification number RA-82906.

According to the notice, devices meant for human use were deployed in animal settings and then returned to Olympus. They were reprocessed there, but the same devices were subsequently issued to hospitals for human clinical use. Health Canada classes the issue under medical devices and sterility.

The affected-products list is long and spans hysteroscopy and gynaecology equipment. It includes OES Pro and OES 4000 hysteroscopy sheaths, OES hysteroscopy telescopes, OES Elite telescopes, grasping forceps, biopsy forceps and hand-instrument scissors. It also covers HD autoclavable camera heads (CH-S190-XZ-E and CH-S200-XZ-EA models), light-guide cables, sterilisation and instrument trays, and Versapoint II electrosurgical components such as the generator, footswitch and connector cable.

Each entry is tied to specific lot or serial numbers and model or catalogue numbers, some of which repeat across several lines. The notice classes the recall under several device categories, including obstetrics and gynaecology, gastroenterology and urology, general and plastic surgery, general hospital use and dental. The audience is healthcare. The only action given is to contact the manufacturer for more information.

As context, a Type II recall in Canada generally covers products that may cause temporary or medically reversible health effects, or where serious harm is considered unlikely. The notice does not describe any patient harm or give details of how many units or hospitals were affected.

What it means for your team

  • Hospital and sterile-processing teams should check loaned and demo Olympus equipment against the lot, serial and catalogue numbers in the Health Canada list.
  • Quality teams should note that the issue stems from allocation and reprocessing controls, not a stated design defect, and may want to review loaner-pool segregation procedures.
  • Regulatory and vigilance staff should track the manufacturer's further communications, as the notice gives no detail on patient impact or the number of units affected.

Official source: Health Canada ↗

Article written by VigiEye from the official source (Health Canada). AI-assisted; check the source before acting.

More Market access All →